RNA Analytical/Quality Articles

1. Antibody–Oligonucleotide Conjugates, Part 1: Approaching Your AOC Development Plan 10/9/2026

   The emergence of antibody–oligonucleotide conjugates (AOCs) addresses delivery issues with huge potential. Let's look at how to approach your development plan with molecular architecture, defining the target product profile, and CQAs.

2. Can Engineering The Passenger Strand Improve siRNA Performance? 10/8/2026

   How can we make the passenger strand easier to reject while keeping the siRNA duplex sufficiently stable before it reaches the machinery that activates it?

3. How Should We Measure The True Potency Of RNA Therapeutics? 10/5/2026

   An RNA therapeutic can generate a strong molecular signal without producing the intended biological function. Let's look at how best to predict whether the RNA has completed its task.

4. Engineering RNA Agonists For Systemic Immunity Without Systemic Toxicity 10/1/2026

   Krieg believes the answer lies in a deeper understanding of innate immune biology and the design of RNA/DNA hybrid mimics of viral RNA and DNA that are detected by innate immune receptors.

5. Why RNA–LNP Development Needs Higher-Resolution Analytics In 2027 9/11/2026

   Raising analytical resolution is among the cheapest interventions available. With regulators tightening and capital selective, it is also among the most consequential.

6. What Oligo Manufacturing Risks Are We Underestimating? 9/8/2026

   Earlier this year, I attended the OPT Congress, where I had the great fortune of meeting consultant Marc Lemaitre. I recently sat down with Lemaitre for a follow-up interview to gauge some of the evolutions he’s been watching within the CMC landscape for oligo development. Here, he digs into the shifts in quality he’s noted, pointing out some of the potential pitfalls we may encounter in our manufacturing that could stand to impact the overall quality of our oligos. 

7. Will 2027 See A Meteoric Rise Of Programmable Nanomedicine? 9/2/2026

   The significance of programmable nanomedicines is not simply that nanoparticles can carry more functions. It is that biological information can become part of the control logic.

8. From Cell State Reprogramming To The Clinic: Turning The Regulatory Genome Into RNA Medicines (Pt. 2) 8/26/2026

   Ounzain discusses how regulatory genome biology is being translated into drug discovery, from identifying lncRNA targets to building clinically relevant therapeutics and more.

9. From Baby KJ To Global Access: The 3 Pillars Of Next-Gen mRNA Expansion 8/8/2026

   Obviously, the transition from RNA vaccines to therapeutics is an “expansion” all on its own; but to do this successfully, we need to expand our science, our products’ deliverability, and our patient access. In the following article, I highlight a few of the best practices and/or innovations that came up in conversation during this event that will play a significant role in helping us expand mRNA’s reach, both scientifically and therapeutically.

10. Building A Self-Driving Lab For LNP Development 7/20/2026

    With commercially available components, MIT researchers built a platform that accelerates LNP process development, optimization, and autonomous manufacturing research.